respiratory

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

Patients

Protecting continuity of care through sustainable respirator...

More attention is being paid to how care can be delivered in ways that maintain continuity for patients while also being environmentally responsible.

News

EU approval for new asthma drug Exdensur lifts GSK

EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.

R&D

steaming nebulizer mask in hand instructing African American daughter

Advancing RSV and hMPV research through human challenge tria...

Human challenge trials offer a complementary approach, and hVIVO has been at the forefront of this field for decades.

News

COPD patients will get access to Dupixent via NHS

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

News

China clears GSK's Nucala for COPD

GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.

Where others missed, AZ's IL-33 drug hits the mark in COPD

Protecting continuity of care through sustainable respirator...

EU approval for new asthma drug Exdensur lifts GSK

Advancing RSV and hMPV research through human challenge tria...

COPD patients will get access to Dupixent via NHS

China clears GSK's Nucala for COPD

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

respiratory

Editor's Picks